International AIDS Society Conference

July 17-20, 2011 - Rome, Italy

Back IAS 2011

Expert Overview from IAS 2011 [VIDEO]

Cal Cohen from the Community Research Institute of New England provides an overview of the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) recently held in Rome, including groundbreaking findings on treatment as prevention as well as data on experimental antiretroviral agents and new strategies for using existing drugs.alt

Read more:

IAS 2011: HIV NNRTI Rilpivirine Effective and Well-Tolerated at 2 Years

The recently approved next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (Edurant) continued to show efficacy comparable to efavirenz (Sustiva) at 96 weeks, but with fewer central nervous system side effects and a more favorable lipid profile in the Phase 3 ECHO and THRIVE trials. alt

Read more:

IAS 2011: Anti-Herpes Drugs Reduce HIV Viral Load, Slow Disease Progression

Several studies presented at the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) last month in Rome showed that treating herpes simplex virus type 2 (HSV-2) with acyclovir or valacyclovir (Valtrex) reduced HIV viral load and slowed disease progression.

alt

Read more:

IAS 2011: People with HIV Have Double Risk for Non-Melanoma Skin Cancers

Several studies conducted in the era of effective antiretroviral therapy (ART) have shown that people with HIV have higher rates of non-AIDS-defining cancers, especially those caused by infectious pathogens such as human papillomavirus or hepatitis B or C.alt

Read more:

IAS 2011: Final iPrEX Analysis Confirms PrEP Effectiveness for Gay Men

Pre-exposure prophylaxis (PrEP) was shown to be highly effective for men and transgender women who have sex with men in a completed analysis of the large iPrEx trial presented at IAS 2011, but the prevention effect was blunted by low levels of adherence.alt

Read more: